Back to today’s briefing

Story perspectives

Pfizer Halts Obesity Drug After Liver Injury Concerns

4/15/2025

50 3

Summary

Story summary

Pfizer has made the difficult decision to halt the development of danuglipron, an oral treatment for obesity, following a potential liver injury in a trial participant. While the patient has since recovered, safety concerns loomed large. Nevertheless, Pfizer remains committed to finding solutions for obesity, focusing on other promising treatments in this expanding market.

1 of 1

Story summary

Pfizer has made the difficult decision to halt the development of danuglipron, an oral treatment for obesity, following a potential liver injury in a trial participant. While the patient has since recovered, safety concerns loomed large. Nevertheless, Pfizer remains committed to finding solutions for obesity, focusing on other promising treatments in this expanding market.